-
Mashup Score: 11What are the Treatment Options for Patients With Lenalidomide-Refractory Myeloma? | Blood Cancers Today - 3 day(s) ago
Donna Catamero, ANP-BC, OCN, CCRC, discusses selinexor for myeloma, the BOSTON trial, and other recent advances in myeloma.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 11MRD Receives Support as a Biomarker for FDA Accelerated Approval in Myeloma Therapies | Blood Cancers Today - 8 day(s) ago
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
The FDA ODAC voted in favor of the use of MRD-negativity as an endpoint for accelerated approval in #myeloma trials. Read more about the vote, with remarks from @DrChrisHourigan (@FralinBiomed), @Dr_RaviMadan (@theNCI), & @MaurerStats (@MayoClinic). đź“– https://t.co/njQmWoGgpN https://t.co/QumEBMq9gF
-
-
Mashup Score: 34Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium - PubMed - 12 day(s) ago
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
#Myeloma Paper of the Day: Study of real world impact of bridging therapy prior to CAR T finds response showed no significant association with CRS, ICANS rates, or 3-month post-CAR-T response, and median PFS didn’t significantly differ based on response: https://t.co/gzVPac99bJ. https://t.co/6fGX2MdpxV
-
-
Mashup Score: 6
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Shandra | Leukemia and Lymphoma Society - 28 day(s) ago
I was diagnosed with multiple myeloma (MM) two years ago. I had never heard of this cancer until I was diagnosed. I found out I had cancer when my T2 vertebra had fractured in my back, and they called the fracture a pathological fracture, meaning an injury didn’t cause it. Every test was run, and it was confirmed that I had cancer. Still in denial, I wanted a second opinion. A second opinion was done, and I had to accept it because I have children ages 19, 10, and 6. I wanted to be here with them as long as possible. Having myeloma hasn’t been easy, but so far, I haven’t been depressed about it because I am still living my life and traveling with my kids. Depression wasn’t an option for me. I believe everything happens for a reason, good and bad. I changed my mindset, and I have been kicking myeloma’s tail for two years. I will be celebrating my 40th birthday on Wednesday, March 30, and I have reached my first remission! I hope it lasts a long time.
Source: lls.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 8Mathura | Leukemia and Lymphoma Society - 1 month(s) ago
I went out to ring in 2023 on New Year’s Eve telling everyone it would be MY year, a time to celebrate new projects and dreams I had been conjuring. A simpler life. Days later, I developed pneumonia, bronchitis, severe muscle pain, and then heart failure from all of it. In March, an x-ray that was supposed to look at my chest for heart failure instead showed lesions and holes from my pelvis to my rib cage, a sign of advanced multiple myeloma (MM) which was confirmed weeks later. I had no idea what it was or what it meant, but luckily, I had friends who were fighting cancer who helped comfort and lead me to better answers than Google. I read through The Leukemia & Lymphoma Society (LLS) website, and a friend helped me get a smart, reassuring second opinion with UCLA with the help of LLS. I’ve had a round of radiation and am on my fifth cycle of chemotherapy. Navigating the appointments, records, insurance, disability, and financial sides of having cancer is something no one is prepared
Source: lls.orgCategories: General Medicine News, Partners & KOLsTweet-
"Navigating appointments, disability, & financial sides of having cancer is something no one is prepared for. Understanding risks & side effects is also confusing for a newly diagnosed #myeloma patient." - In memory, Mathura. Read his full story 👉 https://t.co/l2TojL1NV9 (1/3) https://t.co/CxJR9VN2HO
-
-
Mashup Score: 4Analysis Suggests Cilta-Cel Is Significantly More Effective Versus Conventional MM Therapies | Blood Cancers Today - 1 month(s) ago
Patients with lenalidomide-refractory multiple myeloma had significant improvements in health-related quality of life and symptom burden after one cilta-cel infusion.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma | Blood Cancers Today - 1 month(s) ago
The panel discussed how CAR-T impacts myeloma standard of care.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
@szusmani @chadinabhan Up next, we're highlighting this roundtable segment on on how CAR-T impacts #myeloma standard of care. Moderator @SagarLonialMD, of @WinshipAtEmory, was joined by @NoopurRajeMD (@MGHCancerCenter, @harvardmed) and @DrKrinaPatel (@MDAndersonNews)! đź“şhttps://t.co/0XT3hWlPOl https://t.co/NnX0jhMVsh
-
Donna Catamero, ANP-BC, OCN, CCRC (@domenica76), of @IcahnMountSinai, stopped by BCT to discuss the efficacy and toxicity management of selinexor, results from the BOSTON trial, and other recent advances in #myeloma. đź“ş Watch her interview here! https://t.co/mLoBgsiTXc https://t.co/sdCPZrcZ6a